Published in
Springer (part of Springer Nature), Advances in Therapy, 11(35), p. 1945-1964, 2018
DOI: 10.1007/s12325-018-0804-z
Links
Tools
Pharmacokinetic effects and safety of olaparib administered with endocrine therapy: A phase I study in patients with advanced solid tumours.
Journal article published in 2018 by
Ruth Plummer,
Henk M. Verheul 
,
Filip Y. F. L. De Vos ,
Karin Leunen,
L. Rhoda Molife,
Christian Rolfo,
Peter Grundtvig-Sørensen,
Jacques De Grève,
Sylvie Rottey,
Guy Jerusalem,
Antoine Italiano,
James Spicer ,
Luc Dirix,
Carsten Goessl,
Joseph Birkett
and other authors.
,
Filip Y. F. L. De Vos ,
Karin Leunen,
L. Rhoda Molife,
Christian Rolfo,
Peter Grundtvig-Sørensen,
Jacques De Grève,
Sylvie Rottey,
Guy Jerusalem,
Antoine Italiano,
James Spicer ,
Luc Dirix,
Carsten Goessl,
Joseph Birkett
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer. This phase I study assessed the safety and pharmacokinetic (PK) profiles of olaparib combined with tamoxifen, anastrozole or letrozole in patients with advanced solid tumours.